Background: Our objective was to use real world data to evaluate of the treatment continuum of bevacizumab (Bmab), cetuximab (Cmab), panitumumab (Pmab) or no biologics across 1^st, 2^nd, and 3^rd lines among metastatic colorectal cancer (mCRC) patients who were treated at community cancer centers in the United States. This objective was applied separately to patients with confirmed KRAS, NRAS, or BRAF wild-type (WT) or mutation (MUT) status, as well as patient who did not receive biomarker testing (UNK). Methods: This descriptive study utilized data from the Oncology Services Comprehensive Electronic Records (OSCER) database. It included 5,446 (2,064 WT, 1,807 MUT, and 1,575 UNK) patients diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patients were stratified into the following mutually-exclusive categories in 1^st, 2^nd line, and 3^rd line: Pmab only, Cmab only, Bmab only, or no biologic. Patients who survived and continued therapy were followed through the lines of therapy. Results: 23.8% of WT, 36.3% of MUT and 49.5% of UNK patients did not receive a biologic in 1^st line. There were 1,003 WT patients who were treated with Bmab in 1^st. Of those, n=587 (58.5%) survived and elected to continue treatment in 2^nd line as follows: n=221 (37.6%) continued with Bmab, n=216 (36.8%) initiated Cmab, n=65 (11.1%) initiated Pmab, and n=85 (14.5%) received no biologic in 2^nd line. Of the 221 WT patients who received Bmab in 1^st and 2^nd line, n=129 (58.4%) survived and initiated 3^rd line treatment, of which n=20 (15.5%) received Bmab in 3^rd line. There were 127/2,604 (4.9%) WT patients who were treated with Pmab in 1^st line. Of those 127 patients, n=46 (36.2%) survived and elected to continue treatment in 2^nd line as follows: n=11 (29.3%) continued treatment with Pmab in 2^nd line, while n=14 (30.4%) initiated treatment with Bmab, n=4 (8.7%) initiated treatment with Cmab, and n=16 (36.4%) did not receive a biologic in 2^nd line. Conclusions: A small proportion of patients continued treatment with the same biologic throughout subsequent lines of therapy. Many patients were not treated with a biologic in any line, even if they were confirmed WT.